Literature DB >> 32542715

Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program.

Evan M Bloch1, Eteri Kipiani2, Shaun Shadaker3, Maia Alkhazashvili2, Lia Gvinjilia4, Tinatin Kuchuloria4, Nazibrola Chitadze2, Sheila M Keating5,6, Amiran Gamkrelidze2, Alexander Turdziladze2, Vladimer Getia2, Muazzam Nasrullah3, Francisco Averhoff3, Mariam Izoria2, Beth Skaggs4.   

Abstract

BACKGROUND: In April 2015, the government of Georgia (country) initiated the world's first national hepatitis C elimination program. An analysis of blood donor infectious screening data was conducted to inform a strategic plan to advance blood transfusion safety in Georgia. STUDY DESIGN AND METHODS: Descriptive analysis of blood donation records (2015-2017) was performed to elucidate differences in demographics, donor type, remuneration status, and seroprevalence for infectious markers (hepatitis C virus antibody [anti-HCV], human immunodeficiency virus [HIV], hepatitis B virus surface antigen [HBsAg], and Treponema pallidum). For regression analysis, final models included all variables associated with the outcome in bivariate analysis (chi-square) with a p value of less than 0.05.
RESULTS: During 2015 to 2017, there were 251,428 donations in Georgia, representing 112,093 unique donors; 68.5% were from male donors, and 51.2% of donors were paid or replacement (friends or family of intended recipient). The overall seroprevalence significantly declined from 2015 to 2017 for anti-HCV (2.3%-1.4%), HBsAg (1.5%-1.1%), and T. pallidum (1.1%-0.7%) [p < 0.0001]; the decline was not significant for HIV (0.2%-0.1%). Only 41.0% of anti-HCV seropositive donors underwent additional testing to confirm viremia. Infectious marker seroprevalence varied by age, sex, and geography. In multivariable analysis, first-time and paid donor status were associated with seropositivity for all four infectious markers.
CONCLUSION: A decline during the study period in infectious markers suggests improvement in blood safety in Georgia. Areas that need further improvement are donor recruitment, standardization of screening and diagnostic follow-up, quality assurance, and posttransfusion surveillance.
© 2020 AABB.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32542715      PMCID: PMC7441849          DOI: 10.1111/trf.15815

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.337


  34 in total

Review 1.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  The burden of out-of-pocket payments for health care in Tbilisi, Republic of Georgia.

Authors:  Jacek Skarbinski; H Kenneth Walker; Laurence C Baker; Archil Kobaladze; Zviad Kirtava; Thomas A Raffin
Journal:  JAMA       Date:  2002-02-27       Impact factor: 56.272

3.  RISK OF POST-TRANSFUSION VIRAL HEPATITIS.

Authors:  G F GRADY; T C CHALMERS
Journal:  N Engl J Med       Date:  1964-08-13       Impact factor: 91.245

4.  Serum hepatitis from whole blood: incidence and relation to source of blood.

Authors:  C M KUNIN
Journal:  Am J Med Sci       Date:  1959-03       Impact factor: 2.378

5.  Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations.

Authors:  J H Walsh; R H Purcell; A G Morrow; R M Chanock; P J Schmidt
Journal:  JAMA       Date:  1970-01-12       Impact factor: 56.272

Review 6.  Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges.

Authors:  Evan M Bloch; Marion Vermeulen; Edward Murphy
Journal:  Transfus Med Rev       Date:  2011-08-26

7.  Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donors.

Authors:  M Butsashvili; T Tsertsvadze; L A McNutt; G Kamkamidze; R Gvetadze; N Badridze
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

8.  Differences between blood donors and a population sample: implications for case-control studies.

Authors:  Jean Golding; Kate Northstone; Laura L Miller; George Davey Smith; Marcus Pembrey
Journal:  Int J Epidemiol       Date:  2013-07-03       Impact factor: 7.196

9.  Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs - Georgia, 2018.

Authors:  Ketevan Stvilia; Philip R Spradling; Alexander Asatiani; Maka Gogia; Khatuna Kutateladze; Maia Butsashvili; Jaba Zarkua; Tengiz Tsertsvadze; Lali Sharvadze; Maia Japaridze; Tinatin Kuchuloria; Lia Gvinjilia; Irinka Tskhomelidze; Amiran Gamkrelidze; Irma Khonelidze; David Sergeenko; Shaun Shadaker; Francisco Averhoff; Muazzam Nasrullah
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-07-26       Impact factor: 17.586

10.  The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia.

Authors:  Tengiz Tsertsvadze; Lali Sharvadze; Nikoloz Chkhartishvili; Lela Dzigua; Marine Karchava; Lana Gatserelia; Akaki Abutidze; Kenrad E Nelson
Journal:  Virol J       Date:  2016-02-03       Impact factor: 4.099

View more
  2 in total

1.  Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.

Authors:  Davit Baliashvili; Francisco Averhoff; Ana Kasradze; Stephanie J Salyer; Giorgi Kuchukhidze; Amiran Gamkrelidze; Paata Imnadze; Maia Alkhazashvili; Gvantsa Chanturia; Nazibrola Chitadze; Roena Sukhiashvili; Curtis Blanton; Jan Drobeniuc; Juliette Morgan; Liesl M Hagan
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

2.  Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.

Authors:  Evan M Bloch; Ruchika Goel; Silvano Wendel; Thierry Burnouf; Arwa Z Al-Riyami; Ai Leen Ang; Vincenzo DeAngelis; Larry J Dumont; Kevin Land; Cheuk-Kwong Lee; Adaeze Oreh; Gopal Patidar; Steven L Spitalnik; Marion Vermeulen; Salwa Hindawi; Karin Van den Berg; Pierre Tiberghien; Hans Vrielink; Pampee Young; Dana Devine; Cynthia So-Osman
Journal:  Vox Sang       Date:  2020-07-20       Impact factor: 2.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.